Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr;37(4):948-951.
doi: 10.1038/s41375-023-01836-w. Epub 2023 Feb 16.

CMV serostatus and T-cell repertoire diversity 5 years after allogeneic hematopoietic stem cell transplantation

Zuleika Calderin Sollet  1 , Antonia Schäfer  1 , Sylvie Ferrari-Lacraz  1 , Stavroula Masouridi-Levrat  2 , Anne-Claire Mamez  2 , Amandine Pradier  2 , Federico Simonetta  2 , Yves Chalandon  2 , Jean Villard  3 , Stéphane Buhler  1
Affiliations

CMV serostatus and T-cell repertoire diversity 5 years after allogeneic hematopoietic stem cell transplantation

Zuleika Calderin Sollet et al. Leukemia. 2023 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

YC: consulting fees from MSD, Novartis, Incyte, BMS, Pfizer, Abbvie, Roche, Jazz, Gilead, Amgen, Astra-Zeneca, Servier; Travel support from MSD, Roche, Gilead, Amgen, Incyte, Abbvie, Janssen, Astra-Zeneca, Jazz. The other authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Overview of the CD4+ and CD8+ T-cell phenotypes and TCR diversity from n = 25 1-year post-HSCT patients (post-Tx.1) and their donors (pre-Tx).
A Frequency of the Tnaive, Tscm, Tcm, Tem, and Temra cells in the CD4+ and CD8+ T-cell populations. Box plots show the median frequency per group, and dots correspond to one subject. B Proportion of Tnaive, Tcm, Tem, and Temra subsets within four sets of donor/recipient pairs (D/R) classified on their CMV serotype (D-/R-, D+/R-, D-/R+ and D+/R+). Only the donor status is reported for pre-Tx data. Each bar plot displays the four T cell subsets distribution in CD4+ and CD8+ compartments at both time points. C Simpson’s clonality of the TCR CDR3β repertoire from CD4+ and CD8+ fractions. Each dot corresponds to a subject and is color-coded according to the CMV serologic status (see B). D Clonal expansion of CMV-specific clonotypes. Box plots show the cumulative frequency of CMV-specific clonotypes. The dot’s size denotes the number of the most abundant CMV-specific clonotypes (i.e., expanded clones with a frequency above 1%). D: donor, R: recipient, (−) CMV negative, (+) CMV positive. Boxes show median and interquartile ranges, and dots correspond to individuals. Dunn’s test was used for multiple comparisons between groups for each T cell fraction. P values below 0.05 were considered statistically significant.
Fig. 2
Fig. 2. Overview of the diversity and overlap of the TCR CDR3β repertoire in 26 donor/recipient pairs as measured by Simpson’s clonality and Morisita’s index, respectively.
A Three time points were considered and compare the repertoire in 10 related and 16 unrelated donors prior to transplantation (pre-Tx), at 1 year post-HSCT in 26 full chimeric recipients (post-Tx.1) and their follow-up at 5 or 6 years (post-Tx.5). At the latter time point, 23 recipients were still fully chimeric, while 3 had mixed chimerism (i.e., recipient chimerism estimated between 7% and 15% in peripheral blood mononuclear cells according to an analysis performed with microsatellite markers). Clonality and Morisita’s values are shown along the y axis with lines connecting donors and recipients. In B, Simpson’s clonality and Morisita’s index are plotted according to CMV serologic status and a documented CMV reactivation or infection (i.e., defined as CMV DNA in plasma above the limit of detection, currently 2.1E + 1 UI/ml, in patients with or without clinical symptoms) within the first year post-transplantation. Of note, no CMV reactivation or infection was documented in the last year prior to the follow-up at 5 or 6 years. The clonal expansion of the repertoire across the three time points is presented in C according to CMV serologic status. The cumulative frequency of clonotypes for a given category is plotted with color representing the level of expansion considered based on the number of sequenced reads. D provides a detailed view of the expansion of the repertoire in the nine D+/R+ pairs. The clonotypes are categorized as “private” (i.e., observed in only one donor/recipient pair of the current cohort) or “public” (i.e., observed in two or more donor/recipient pairs) and the data are stratified according to occurrence of CMV reactivation or infection within the first year post-transplantation. D: donor CMV negative (−) or positive (+), R: recipient CMV negative (−) or positive (+), Inf: CMV reactivation or infection within the first year post transplantation, Tx: allogeneic HSCT.
See this image and copyright information in PMC

References

    1. Michalek J, Collins RH, Hill BJ, Brenchley JM, Douek DC. Identification and monitoring of graft-versus-host specific T-cell clone in stem cell transplantation. Lancet. 2003;361:1183–5. doi: 10.1016/S0140-6736(03)12917-0. - DOI - PubMed
    1. Fry TJ, Mackall CL. Immune reconstitution following hematopoietic progenitor cell transplantation: challenges for the future. Bone Marrow Transpl. 2005;35:S53–S7. doi: 10.1038/sj.bmt.1704848. - DOI - PubMed
    1. Krenger W, Blazar BR, Hollander GA. Thymic T-cell development in allogeneic stem cell transplantation. Blood. 2011;117:6768–76. doi: 10.1182/blood-2011-02-334623. - DOI - PMC - PubMed
    1. Seggewiss R, Einsele H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood. 2010;115:3861–8. doi: 10.1182/blood-2009-12-234096. - DOI - PubMed
    1. Huttunen P, Taskinen M, Siitonen S, Saarinen-Pihkala UM. Impact of very early CD4(+) /CD8(+) T cell counts on the occurrence of acute graft-versus-host disease and NK cell counts on outcome after pediatric allogeneic hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2015;62:522–8. doi: 10.1002/pbc.25347. - DOI - PubMed

Publication types

MeSH terms